Status:
UNKNOWN
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
Lead Sponsor:
lihegen
Conditions:
NSCLC
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Objective: To study the effect of Jinfukang Koufuye combined with chemotherapy on preventing relapse and metastasis of early postoperative NSCLC patients. Method: In this multicenter、prospective、rando...
Eligibility Criteria
Inclusion
- Pathology-confirmed diagnosis of primary NSCLC with complete resection, and stage IB-IIB
- Accept chemotherapy for the first time 6 weeks after operation
- Age of 18-75 years old
- Eastern Cooperative Oncology Group-PS≤2
- N\>1.5×109/L、PLT\> 100 × 109/L、Hb\>100g/dL、Liver and kidney function is normal or elevated ≤ 1.5 times
- Voluntary participation in the prospective study with signed informed consent
Exclusion
- No pathology-confirmed diagnosis patients
- Patients with overall survival time\<6 months
- Patients with Serious diseases like heart、liver、kidney and hematopoietic system at the same time
- Pregnant or breast feeding patients
- Patients with uncontrollable mentally disease
- Patients with diabetes
Key Trial Info
Start Date :
September 30 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2019
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT03269162
Start Date
September 30 2016
End Date
September 30 2019
Last Update
September 14 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.